Becker's Healthcare September 12, 2024
Claire Wallace

The FDA has approved Johnson & Johnson’s Tremfya to treat adults with moderate to severe ulcerative colitis.

It is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23, which is a driver...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
1st gene therapy delivered directly into brain approved
How HHS, FDA, and CDC Can Influence U.S. Vaccine Policy
Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval
New FDA rules for TV drug ads to take effect: 4 things to know
Artificial heart saves 4th patient

Share This Article